Search

Background:Iris claw phakic intraocular lens [PIOL] is one of the surgical techniques used for the correction of high myopia. This procedure reduces myopia with stable refractive results and preserves the accommodation. Aim of the Work:The aim of this study is to assess the outcome of foldable and hard [PMMA] iris claw PIOL implantation as one of surgical procedures in the management of high myopic young patients. Patients and Methods:A prospective comparative study having foldable and hard [PMMA] iris claw phakic intraocular lens [PIOL] for correction of high myopia. This study includes forty eyes [40 eyes] of twenty high myopic patients [20 pt.] with refraction range of [-10.0 D to -25.0 D] without or with cylinder not more than [-2.0 D]. The patients were divided to two groups [A] and [B], each group contains twenty [20] eyes, the first 20 eyes [group A] received a concave-convex foldable iris claw PIOL and the remaining 20 eyes [group B] received a biconcave optic hard PMMA iris claw PIOL. Result:The mean postoperative SE at 6 months in group [A] was [-0.30 ± 0.10 D] within ±1.00 D of emmetropia. In group [B] it was [- 0.50 ± 0.50 D] within ±1.0 D of emmetropia. The mean postoperative cylinder at 6 months was [-0.31 ± 0.10] in group [A], and [-0.51 ± 0.51] in group [B]. There was a statistically significant difference between preoperative UCVA and postoperative UCVA at 6 months were [p

Background: strabismus is a condition in which the eyes are not properly aligned with each other. It typically involves a lack of coordination between the extraocular muscles. Strabismus can present as manifest (heterotropia), apparent, latent (heterophoria) varieties. Objective: the present study aimed to compare the minimally invasive strabismus surgery (MISS) as an alternative to limbal approach for horizontal concomitant strabismus. Patients and Methods: the study included 50 patients of different ages and sexes, presented with transverse strabismus, for elective surgical correction. They allocated into two equal groups; the first group included 25 cases who were managed by MISS (patients group); the second group included the other 25 cases who were managed by limbal approach (control group). Results: the results were evaluated at one week, three week and six week as regards to visibility of surgical wound, post-operative conjuntival redness, patient discomfort, surgical opening related complications and post-operative correction at first week, third and six months. Few complications were seen with the MISS technique and they were mostly related to the surgery not to the technique itself. Conclusion: the minimally invasive strabismus surgery has the same effect as limbal approach as obvious by the similar success rate. Its stability is as good as the stability of limbal incision. It has the advantages of sparing perilimbal episcleral vessles which make it a good choice instead of limbal approach whenever there is fear of anterior segment ischemia.

Background: Diabetic macular edema is one of the most significant causes of blindness and severe visual impairment in patients with diabetes, which can result in reduced quality of life. Three commonly used intravitreous VEGF inhibitors aflibercept, bevacizumab and ranibizumab have been shown to be beneficial and relatively safe for the treatment of diabetic macular edema, but only aflibercept and ranibizumab are approved by the Food and Drug Administration (FDA) for this indication. Aim of the Work: To compare between the effect of ranibizumab and aflibercept in patients with diabetic macular edema as a diabetic retinopathy complication that leads to visual impairment. Patients and Methods: A prospective study of 20 patients (20 eyes) was conducted in Al-Mouneer diabetic eye center with three times injection one month apart. The patients were divided into two groups, Group A was consisted of 10 patients who received ranibizumab as 0.5 mg (0.05ml of 10mg/ml solution) an intra vitreal injection. Group B was consisted of 10 patients who received aflibercept 2 mg (0.05mL of 40mg/ml solution) as an intra vitreal injection with follow up for three months. Results: A statistically significant difference over the time through BCVA and central macular thickness with ranibizumab. There was also a statistically significant difference over the time through BCVA, central macular thickness and IOP with aflibercept. Conclusion: There was more improvement in BCVA which was significant and more reduction in central macular thickness with ranibizumab than with aflibercept. Recommendations: Larger group studies to confirm our results; longer term study for the effect of ranibizumab and aflibercept injection on the central macular thickness and IOP and comparing the effect of single injection versus multiple injections. Searching for the causes of resistance or delayed response to the intravitreal injections in some patients.